INBX Inhibrx Biosciences Inc.

QT15

Latest market price

71.78

-1.87-2.54%

Overview Short InterestFilings

INBXQT15Inhibrx Biosciences Inc.·NASDAQ

Overview Short InterestFilings

71.78-2.54%

Loading chart...

Signal & projected range

Gap down — mean-reversionHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

TRAX-0.33%$45.08 NVAX-3.72%$10.08 NUVB-0.21%$4.76 KLRA-4.10%$12.86 REPL+1.27%$17.61 STOK-0.23%$26.29 QURE-1.86%$24.83 NTLA-5.74%$12.47

Snapshot

Index	—	P/E	—	EPS (ttm)	-1.51	Insider Own	—	Shs Outstand	14.72M	Perf Week	-23.13%

Market Cap	1.06B	Forward P/E	—	EPS next Y	-8.94	Insider Trans	0.31%	Shs Float	10.96M	Perf Month	-26.70%

Enterprise Value	928.43M	PEG	—	EPS next Q	-2.45			Short Float	31.19%	Perf Quarter	-13.23%

Income	-140.00M	P/S	—	EPS this Y	—			Short Ratio	12.27	Perf Half Y	-44.27%

Sales	1.00M	P/B	—	EPS next Y	—	ROA	-89.60%	Short Interest	3.42M	Perf YTD	-9.14%

Book/sh	-3.60	P/C	7.94	EPS next 5Y	—	ROE	—	52W High	155.29 -53.78%	Perf Year	-6.84%

Cash/sh	9.04	P/FCF	—	EPS past 3/5Y	—	ROIC	-99.35%	52W Low	57.30 25.27%	Perf 3Y	—

Dividend Est.	—	EV/EBITDA	—	Sales past 3/5Y	-20.63% -40.13%	Gross Margin	0.00%	Volatility	12.71% 7.06%	Perf 5Y	—

Dividend TTM	—	EV/Sales	—	EPS Y/Y TTM	—	Oper. Margin	0.00%	ATR (14)	7.51	Perf 10Y	—

Dividend Ex-Date	May 30, 2024	Quick Ratio	5.07	Sales Y/Y TTM	-100.00%	Profit Margin	0.00%	RSI (14)	31.17	Recom	2.40

Dividend Gr. 3/5Y	—	Current Ratio	5.07	EPS Q/Q	-26.49%	SMA20	-19.76%	Beta	1.98	Target Price	285.00

Payout	0.00%	Debt/Eq	—	Sales Q/Q	-100.00%	SMA50	-29.86%	Rel Volume	1.44	Prev Close	73.65

Employees	110	LT Debt/Eq	—	Earnings	Nov 13	SMA200	-22.10%	Avg Volume	304.59K	Price	71.78

IPO Date	May 29, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	-2.63% —	Net Debt/EBITDA	—	Volume	438,818	Change	-2.54%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Aug-24-26	Initiated	H.C	Buy	$245
May-15-26	Reiterated	Stifel Nicolaus		$300
Jan-23-24	Downgrade	JMP Securities	Market Outperform → Market Perform

Latest News· Times ET

Oct-28-26

Oct-28-2601:30PM

US Top Movers: Biggest Gainers and Decliners in Today's SessionChartMill

Oct-27-26

Oct-27-2604:13AM

Inhibrx Biosciences (NASDAQ:INBX) Shares Cross Below 200-Day Moving Average – Here’s What Happeneddefenseworld.net

Oct-21-26

Oct-21-2601:54PM

Insiders Load Up on These 2 ‘Strong Buy’ Stocks — Should You Follow Their Footsteps?Yahoo

Oct-14-26

Oct-14-2610:14AM

Are Inhibrx Biosciences' (INBX) Global Data Reveals Reframing Its Late-Stage Pipeline Credibility?Yahoo

Oct-13-26

Oct-13-2604:00PM

Inhibrx Announces Participation in Upcoming Scientific Conferencesprnewswire.com

Oct-05-26

Oct-05-2608:14AM

Connect Biopharma (NASDAQ:CNTB) & Inhibrx Biosciences (NASDAQ:INBX) Critical Contrastdefenseworld.net

Oct-02-26

Oct-02-2608:00AM

Inhibrx's Insider Buying Adds Fuel to a High-Short-Interest Biotech Setupmarketbeat.com

Sep-30-26

Sep-30-2606:44AM

Inhibrx Biosciences (NASDAQ:INBX) Shares Climb 3.7% on Insider Buying Activitydefenseworld.net

06:00AM

Inhibrx Biosciences (NASDAQ:INBX) Stock Price Up 3.7% Following Insider Buying Activitydefenseworld.net

Sep-29-26

Sep-29-2607:08AM

Inhibrx Biosciences (INBX) Faces A Pipeline Valuation Test Following Its Sharp ReratingYahoo

Sep-25-26

Sep-25-2604:23AM

Inhibrx Biosciences (NASDAQ:INBX) Stock: Insider Jon Faiz Kayyem Buys 5,000 Sharesdefenseworld.net

Sep-24-26

Sep-24-2601:07PM

Inhibrx’s Cancer Drug Nearly Doubled Response Rate, So Why Did the Stock Fall?Yahoo

Sep-20-26

Sep-20-2605:10AM

Insider Buying: Inhibrx Biosciences (NASDAQ:INBX) Director Purchases $500,000.00 in Stockdefenseworld.net

Sep-15-26

Sep-15-2608:09PM

Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?fool.com

Sep-14-26

Sep-14-2609:46AM

Inhibrx: 'Strong Buy' Maintained With Ozekibart Action Date On The Horizon And Study Win With INBRX-106seekingalpha.com

Company

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018	FY 2017 12/31/2017
Total Revenue	1	0	2	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	2	2	1	—	—	—	—	—	—
Gross Profit	-1	-2	1	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	23	128	29	—	—	—	—	—	—
Research and Development	113	204	191	—	—	—	—	—	—
Other Operating Expense	-2	-3	0	—	—	—	—	—	—
Operating Income	-135	-331	-219	—	—	—	—	—	—
Interest Expense	12	13	32	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	7	2,033	11	—	—	—	—	—	—
Net Income Before Taxes	-140	1,688	-240	—	—	—	—	—	—
Income Taxes	0	0	0	—	—	—	—	—	—
Consolidated Net Income	-140	1,688	-241	—	—	—	—	—	—
Net Income From Continuing Operations	-140	1,688	-240	—	—	—	—	—	—
Net Income	-140	1,688	-241	—	—	—	—	—	—
EPS (Recurring)	-9.04	116.58	-5.12	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-9.04	116.58	-5.12	—	—	—	—	—	—
EPS (Diluted)	-9.04	116.58	-5.12	—	—	—	—	—	—
EBITDA	-125	1,703	-207	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	0.13	—	—	—	—	—	—	—
Price To Sales Ratio	1,185.00	—	893.00	—	—	—	—	—	—
Gross Margin	-100.00	—	50.00	—	—	—	—	—	—
Operating Margin	-13,500.00	—	-10,950.00	—	—	—	—	—	—
Net Margin	-14,000.00	—	-12,050.00	—	—	—	—	—	—
Shares Outstanding	15	14	47	—	—	—	—	—	—
Market Capitalization	1,185	216	1,786	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lappe Mark	Chief Executive Officer	Oct 14 '26	Buy	84.56	10,040	848,977	745,588	Oct 14
Lappe Mark	Chief Executive Officer	Sep 28 '26	Buy	100.76	4,500	453,426	740,548	Sep 28
Lappe Mark	Chief Executive Officer	Sep 25 '26	Buy	99.16	5,500	545,357	736,048	Sep 28
Kayyem Jon Faiz	Director	Sep 23 '26	Buy	100.00	5,000	500,000	434,360	Sep 23
Kayyem Jon Faiz	Director	Sep 16 '26	Buy	100.00	5,000	500,000	429,360	Sep 17
MANHARD KIMBERLY	Director	Sep 15 '26	Sale	105.05	500	52,525	7,500	Sep 15
MANHARD KIMBERLY	Director	Sep 14 '26	Sale	110.26	500	55,130	8,000	Sep 15
MANHARD KIMBERLY	Director	Sep 11 '26	Sale	111.78	500	55,888	8,500	Sep 15
MANHARD KIMBERLY	Director	Sep 09 '26	Sale	115.80	500	57,898	9,000	Sep 10
MANHARD KIMBERLY	Director	Sep 08 '26	Sale	115.14	500	57,570	9,500	Sep 10
Lappe Mark	Chief Executive Officer	Sep 08 '26	Buy	105.82	25,000	2,645,399	730,548	Sep 08
Kayyem Jon Faiz	Director	Sep 08 '26	Buy	113.52	5,000	567,580	424,360	Sep 08
FORSYTH DOUGLAS	Director	Sep 08 '26	Buy	114.65	2,500	286,617	227,064	Sep 08
VIKING GLOBAL INVESTORS LP	10% Owner	Oct 07 '25	Sale	32.25	350,000	11,287,501	67,018	Oct 09
Kayyem Jon Faiz	Director	Nov 20 '24	Buy	14.19	18,750	266,102	69,843	Nov 22

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.